How fast does Boey work compared to regular Botox?

Boey is designed to achieve visible results faster than conventional Botox, which typically takes 3–7 days for full effect. The exact onset timeline for Boey hasn't been specified in the EU approval announcement, but the product's core advantage is accelerated neuromuscular blockade diffusion through optimized formulation chemistry.

When will Boey be available in the United States?

Boey has received EU regulatory clearance, which typically signals an incoming FDA submission for U.S. approval. No official FDA timeline has been announced yet, but practices should monitor AbbVie's regulatory announcements for potential domestic availability.

Will Boey replace Botox or require practices to stock both?

Boey is likely to fragment the neuromodulator market by onset profile rather than replace Botox entirely. Practices may need to stock both products or educate patients on premium pricing for faster results, depending on their patient demand and practice model.

What does rapid-onset botulinum toxin mean for pricing?

Faster onset typically commands premium pricing in the aesthetics market. Practices will need to decide whether the speed advantage justifies higher per-unit costs or whether existing patient satisfaction with standard Botox remains sufficient for their revenue model.

Does AbbVie have an advantage launching Boey over competitors?

Yes—AbbVie's scale and existing Botox infrastructure position it to capture market share quickly once FDA approval is granted. The company's established distribution and provider relationships give it a significant competitive edge in rapid adoption.

Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →

RegulatoryAbbVie Launches Phase 2 Forehead Lines Studytoday MarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days ago Business & M&AAllergan Aesthetics Overhauls Loyalty Programtoday Devices & TechXERF Technology Enters Australian Market for Skin Tightening2 days ago Business & M&AEvolus Expands Estyme to Canada, Australia, New Zealandtoday MarketArm Fat Now Top Body Sculpting Concern in Singapore2 days ago Devices & TechSofwave Hits One Million Treatments Milestonetoday RegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days ago RegulatoryRevance Wins FDA Nod for Under-Eye Injectablesyesterday MarketGLP-1 Pill Era Is Forcing Beauty Market Shiftyesterday InjectablesAEON Releases Expanded ABP-450 Botox Biosimilar Datayesterday Devices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday

Regulatory

AbbVie Wins EU Approval for Boey, Its Rapid-Onset Botulinum Toxin

Allergan's new neuromodulator formulation clears European regulators, setting stage for potential U.S. launch and competitive pressure on onset time.

By Evan at Inside MedSpa · Jul 24, 2026

1-YEAR MOVE

ABBV ▲11.6%

1-year price move by ticker
Ticker	Company	1-year change
ABBV	AbbVie (Allergan Aesthetics)	+11.6%

AbbVie's Boey, a rapid-onset botulinum toxin formulation, has received regulatory clearance in Europe. Boey is designed to achieve visible results faster than conventional Botox, addressing a key patient pain point: the 3–7 day wait for full effect. The mechanism relies on optimized formulation chemistry to accelerate neuromuscular blockade diffusion.

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/abbvie-boey-eu-approval-rapid-onset-botox/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →

AbbVie Wins EU Approval for Boey, Its Rapid-Onset Botulinum Toxin

Share

Discussion

Leave a comment

By the time it's news, it's too late.